Methylene Blue as a Vasoplegic Syndrome preventive agent in cardiac surgeries
- Conditions
- Postoperative vasoplegic syndromeH02.403.810.803
- Registration Number
- RBR-96ch27c
- Lead Sponsor
- Hospital das clínicas da Faculdade de Medicina da Universidade de São Paulo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Age 18 years or older; cardiac surgery with cardiopulmonary bypass; EUROSCORE II between 4% and 15%; patient undergoing double valve repair and/or double valve replacement surgery or reoperation in valve surgery or combined surgery (coronary bypass graft with valve surgery) or valve replacement due to endocarditis.
Refusal to participate in the study; patient involved in another clinical trial; emergency surgery; minimally invasive or transcatheter cardiac surgery; cardiac surgery with no cardiopulmonary bypass; change in surgical planning, such as single valve replacement/repair or isolated revascularization; previous or current use of selective serotonin reuptake inhibitor drugs, or selective and non-selective monoamine oxidase inhibitor drugs, or non-selective heterocyclic monoamine reuptake inhibitor drugs; patient with glucose-6-phosphate dehydrogenase deficiency or other hemolytic disease; previous history of hypersensitivity to methylene blue; acute liver dysfunction; pregnancy or potential risk of pregnancy; current use of vasoactive amines.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A reduction in the average daily dosage of vasoactive agents is expected, calculated using a specific formula through the infusion rates records of vasoactive amines in postoperative balances, during the five days following the intervention. A reduction of 0.10 micrograms per kilogram per min in dosage is expected.
- Secondary Outcome Measures
Name Time Method